Login to Your Account

Phase III failure for heart surgery drug crashes Tenax shares

By Michael Fitzhugh
Staff Writer

Tuesday, January 31, 2017

Shares of Tenax Therapeutics Inc. (NASDAQ:TENX) fell 76.4 percent Tuesday on news that its lead candidate, levosimendan, failed to meet the co-primary endpoints of a phase III study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription